Daunomycin treatment prevents clinical expression of experimental autoimmune myasthenia gravis

Premkumar Christadoss, Regina Henderson, Steve Keve

Research output: Contribution to journalArticle

3 Scopus citations


Myasthenia gravis (MG) is an autoimmune neuromuscular disease, characterized by muscle weakness and electrophysiological abnormality. No treatment which would reliably induce permanent clinical remission of MG is yet available. The therapeutic efficacy and toxic effect of daunomvcin (Dm), an antibiotic of the rhodomycin group, was evaluated in murine experimental autoimmune MG. Low dosage Dm treatment effectively prevented the development of muscle weakness and its associated electrophysiological abnormality, without inducing detectable toxicity and global immunosuppression.

Original languageEnglish (US)
Pages (from-to)246-255
Number of pages10
JournalClinical Immunology and Immunopathology
Issue number2
StatePublished - May 1991


ASJC Scopus subject areas

  • Immunology and Allergy
  • Pathology and Forensic Medicine
  • Immunology

Cite this